Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Share This Author
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
- B. Druker, M. Talpaz, C. Sawyers
- Medicine, BiologyThe New England journal of medicine
- 5 April 2001
TLDR
Acute myeloid leukemia.
- F. Giles, A. Keating, A. Goldstone, I. Avivi, C. Willman, H. Kantarjian
- BiologyHematology. American Society of Hematology…
- 2002
TLDR
Revised international prognostic scoring system for myelodysplastic syndromes.
- P. Greenberg, H. Tuechler, D. Haase
- MedicineBlood
- 20 September 2012
TLDR
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
- S. O’Brien, F. Guilhot, B. Druker
- Medicine, BiologyThe New England journal of medicine
- 13 March 2003
TLDR
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
- B. Druker, F. Guilhot, R. Larson
- Medicine, BiologyThe New England journal of medicine
- 7 December 2006
TLDR
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
- M. Baccarani, M. Deininger, R. Hehlmann
- MedicineBlood
- 8 August 2013
TLDR
Clinical effect of point mutations in myelodysplastic syndromes.
- R. Bejar, K. Stevenson, B. Ebert
- Medicine, BiologyThe New England journal of medicine
- 30 June 2011
TLDR
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
- B. Druker, C. Sawyers, M. Talpaz
- MedicineThe New England journal of medicine
- 5 April 2001
TLDR
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
- J. Cools, D. DeAngelo, D. Gilliland
- Medicine, BiologyThe New England journal of medicine
- 27 March 2003
TLDR
Decitabine improves patient outcomes in myelodysplastic syndromes
- H. Kantarjian, J. Issa, H. Saba
- Medicine, BiologyCancer
- 15 April 2006
Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly…
...
...